1. Home
  2. HEI vs ARGX Comparison

HEI vs ARGX Comparison

Compare HEI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEI
  • ARGX
  • Stock Information
  • Founded
  • HEI 1957
  • ARGX 2008
  • Country
  • HEI United States
  • ARGX Netherlands
  • Employees
  • HEI N/A
  • ARGX N/A
  • Industry
  • HEI Aerospace
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HEI Industrials
  • ARGX Health Care
  • Exchange
  • HEI Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • HEI 44.4B
  • ARGX 48.2B
  • IPO Year
  • HEI N/A
  • ARGX 2017
  • Fundamental
  • Price
  • HEI $317.70
  • ARGX $812.69
  • Analyst Decision
  • HEI Buy
  • ARGX Strong Buy
  • Analyst Count
  • HEI 12
  • ARGX 18
  • Target Price
  • HEI $345.36
  • ARGX $813.82
  • AVG Volume (30 Days)
  • HEI 269.9K
  • ARGX 352.6K
  • Earning Date
  • HEI 08-25-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • HEI 0.08%
  • ARGX N/A
  • EPS Growth
  • HEI 34.01
  • ARGX N/A
  • EPS
  • HEI 4.57
  • ARGX 18.75
  • Revenue
  • HEI $4,289,298,000.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • HEI $16.24
  • ARGX $81.74
  • Revenue Next Year
  • HEI $9.79
  • ARGX $31.91
  • P/E Ratio
  • HEI $69.32
  • ARGX $39.03
  • Revenue Growth
  • HEI 13.46
  • ARGX 88.04
  • 52 Week Low
  • HEI $216.68
  • ARGX $510.06
  • 52 Week High
  • HEI $338.92
  • ARGX $855.46
  • Technical
  • Relative Strength Index (RSI)
  • HEI 53.21
  • ARGX 58.92
  • Support Level
  • HEI $311.51
  • ARGX $807.42
  • Resistance Level
  • HEI $319.91
  • ARGX $855.46
  • Average True Range (ATR)
  • HEI 7.47
  • ARGX 16.57
  • MACD
  • HEI 0.45
  • ARGX -2.36
  • Stochastic Oscillator
  • HEI 72.49
  • ARGX 41.12

About HEI Heico Corporation

Heico is an aerospace and defense supplier that focuses on creating replacement parts for commercial aircraft and components for defense products. In commercial aerospace, Heico is the largest independent producer of replacement aircraft parts. In the defense market, the company produces niche subcomponents used in targeting technology as well as simulation equipment, among other categories. It operates as two segments: the flight support group,or FSG, and the electronic technologies group, or ETG, both of which supply the aerospace and defense sectors to different degrees. The company is persistently acquisitive, focusing on companies in similar or adjacent markets that offer strong cash flow and profitable growth potential.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: